Mylan snaps up HIV-focused South African facility from Ascendis for $9.4M

Ascendis decided to let the Johannesburg facility go due to its low utilization and to reduce the complexity of the company’s pharma operations in South Africa. (Thissatan/iStock/GettyImagesPlus/GettyImages)

Global pharma giant Mylan shelled out $9.4 million for Ascendis Health’s South African manufacturing plant that is focused on producing antiretrovirals to combat HIV.

The deal was first reported last month in South Africa. Mylan is expected to create a state-of-the-art manufacturing center at the plant located at Isando in Johannesburg for the production of antiretrovirals, Fin24 reported.

Ascendis’ chief executive, Thomas Thomsen, told the publication that the company decided to let the roughly 90,000-square-foot facility go due to its low utilization and to reduce the complexity of Ascendis’ pharma operations in South Africa.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Ascendis assumed ownership of the plant in 2015 as part of its $24.6 million deal to acquire Akacia Healthcare. The facility has the capacity to produce regular pills, effervescent tablets, semisolid and hard gelatin capsules.

“Mylan has invested significantly in its scientific platform and created broad capacity for global ARV supply,” Rajiv Malik, Mylan’s president, told Creamer Media’s Engineering News, adding that Mylan’s global HIV initiative is one of its key priorities.

“Mylan’s innovations have helped fuel a steep decline in ARV drug costs over the last decade, and the integration of the Isando site into our global manufacturing network will help us meet unmet patient needs in South Africa,” he said.

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.